Teleflex (NYSE:TFX) Price Target Raised to $138.00

Teleflex (NYSE:TFX) had its price target lifted by Wells Fargo & Company from $130.00 to $138.00 in a research note issued to investors on Friday,Benzinga reports. They currently have an equal weight rating on the medical technology company’s stock.

TFX has been the topic of a number of other research reports. Zacks Research raised Teleflex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Wall Street Zen raised Teleflex from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. Needham & Company LLC upped their price objective on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Bank of America raised Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price objective on the stock in a research report on Monday, April 13th. Finally, Royal Bank Of Canada raised Teleflex from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $135.00 to $155.00 in a research report on Friday. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Teleflex currently has a consensus rating of “Hold” and a consensus target price of $142.86.

Teleflex Stock Up 0.1%

Shares of NYSE TFX opened at $133.17 on Friday. Teleflex has a 52-week low of $100.18 and a 52-week high of $139.67. The business’s 50 day moving average is $119.44 and its two-hundred day moving average is $116.73. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82. The firm has a market cap of $5.89 billion, a price-to-earnings ratio of -5.84, a PEG ratio of 0.96 and a beta of 0.82.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.18. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The business had revenue of $548.30 million for the quarter, compared to analyst estimates of $536.91 million. During the same quarter in the prior year, the company earned $1.44 earnings per share. The company’s revenue was up 32.3% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Research analysts predict that Teleflex will post 6.75 EPS for the current year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Friday, March 6th were paid a dividend of $0.34 per share. The ex-dividend date was Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.0%. Teleflex’s payout ratio is presently -5.96%.

Hedge Funds Weigh In On Teleflex

Institutional investors and hedge funds have recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB grew its stake in shares of Teleflex by 57.9% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock worth $26,000 after purchasing an additional 77 shares in the last quarter. Banque Cantonale Vaudoise boosted its stake in Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after acquiring an additional 113 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in Teleflex by 248.8% in the third quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after acquiring an additional 199 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Teleflex in the third quarter valued at $35,000. Finally, V Square Quantitative Management LLC acquired a new position in Teleflex in the fourth quarter valued at $37,000. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex News Roundup

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex beat Q1 estimates, reporting adjusted EPS of $1.39 versus $1.21 expected and revenue of $548.3 million versus $536.9 million expected, which signals solid execution in the quarter. Article Title
• Positive Sentiment: The company maintained its full-year 2026 outlook and announced plans for a buyback, which can support investor confidence and share price performance. Article Title
• Positive Sentiment: Wells Fargo raised its price target on TFX from $130 to $138, implying modest upside from current levels and suggesting improved analyst sentiment. Article Title
• Neutral Sentiment: Management’s earnings call commentary was described as balanced, with growth offset by margin strain, indicating the business is still navigating profitability pressure even after the earnings beat. Article Title
• Negative Sentiment: Teleflex’s updated FY2026 EPS guidance of $6.25 to $6.55 came in below the market’s expectation of about $6.73, which could limit enthusiasm despite the quarterly beat. Article Title

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.